NCM·Healthcare·$93M·#519 / 520 in Healthcare
INO Inovio Pharmaceuticals, Inc.
9CRITICAL
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY29
VALUATION0
GOVERNANCE2
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-70.0%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
6 months
10
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
38.9%
66
< 25% strong
Price / Sales
Market cap relative to trailing revenue
1417.2x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-132941
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
0.4%
3
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+122.5%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE INO WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when INO's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.